Product Images Emtricitabine And Tenofovir Disoproxil Fumarate

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 3 images provide visual information about the product associated with Emtricitabine And Tenofovir Disoproxil Fumarate NDC 82009-109 by Quallent Pharmaceuticals Health Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 200 mg/300 mg (30 Tablet Bottle) - emtriteno fig1

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 200 mg/300 mg (30 Tablet Bottle) - emtriteno fig1

Emtricitabine and Tenofovir Disoproxil Fumarate Tablets is a medication that contains 200 mg of Emtricitabine and 300 mg of Tenofovir Disoproxil Fumarate, equivalent to Tenofovir Isoproxil 245 mg, per film-coated tablet. It should be stored at 20°C to 25°C (66°F to 77°F). The medication guide must be dispensed separately to each patient. This medication is manufactured by Aurobindo Pharma Limited, Hyderabad-500 090, India, and distributed by Quallent Pharmaceuticals Health LLC, Grand Cayman, Cayman Islands. The usual dosage should be referred to in the package insert. The container must be tightly closed and the medication must be dispensed only in the original container. The product comes in a pack of 30 tablets, identified by NDC 82009-109-30. Information such as GTIN, Serial Number, Expiry Date, and LOT will be printed during the packing period.*

Chemical Structure-1 - emtriteno str1

Chemical Structure-1 - emtriteno str1

Chemical Structure-2 - emtriteno str2

Chemical Structure-2 - emtriteno str2

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.